Multilevel Barriers to HIV PrEP Uptake and Adherence Among Black and Hispanic/Latinx Transgender Women in Southern California

Adedotun Ogunbajo, Erik D Storholm, Allison J Ober, Laura M Bogart, Cathy J Reback, Risa Flynn, Phoebe Lyman, Sheldon Morris, Adedotun Ogunbajo, Erik D Storholm, Allison J Ober, Laura M Bogart, Cathy J Reback, Risa Flynn, Phoebe Lyman, Sheldon Morris

Abstract

Black and Hispanic/Latinx transgender women in the United States (U.S.) are disproportionately affected by HIV. Pre-exposure prophylaxis (PrEP) reduces risk of HIV infection but PrEP uptake remains low among Black and Hispanic/Latinx transgender women. Between July 2018 and August 2019, we conducted individual interviews with 30 Black and Hispanic/Latinx transgender women who were prescribed PrEP through a PrEP demonstration project and 10 healthcare providers who provide PrEP services to transgender women in Los Angeles and San Diego, California. The interviews assessed general attitudes, experiences, and beliefs about PrEP as well as individual-, interpersonal-, community-, and structural-level barriers to PrEP uptake and adherence. PrEP adherence was assessed by collecting quantitative intracellular tenofovir-diphosphate (TFV-DP) levels in retrospect on batched, banked dried blood spot (DBS) samples. We utilized qualitative content analysis to identify themes from the interviews. Findings indicated the presence of individual-level barriers including cost concerns, mental health issues, substance use, and concerns about PrEP side effects including hormone interaction. Interpersonal-level barriers included the influence of intimate/romantic partners and the impact of patient-provider communication. Community-level barriers consisted of experiencing stigma and negative community opinions about PrEP use as well as having negative experiences in healthcare settings. Structural-level barriers included unreliable transportation, employment, and housing insecurity. Interventions aiming to increase PrEP uptake and adherence among Black and Hispanic/Latinx transgender women in the U.S. should employ a multilevel approach to addressing the needs of transgender women, especially the structural barriers that have greatly limited the use of PrEP.

Keywords: Black; HIV prevention; Hispanic/Latinx; PrEP adherence; Transgender women.

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose and have no conflicts of interest to declare that are relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Socioecological barriers to PrEP uptake and adherence among Black and Hispanic/Latinx transgender women in Southern California

References

    1. Control CfD, Prevention. HIV and transgender people. CDC website. 2019.
    1. Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. Am J Public Health. 2019;109(1):e1–e8. doi: 10.2105/AJPH.2018.304727.
    1. Poteat T, Reisner SL, Radix A. HIV epidemics among transgender women. Curr Opin HIV AIDS. 2014;9(2):168–173. doi: 10.1097/COH.0000000000000030.
    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–2599. doi: 10.1056/NEJMoa1011205.
    1. Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2(12):e512–e519. doi: 10.1016/S2352-3018(15)00206-4.
    1. Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340. doi: 10.1097/QAI.0000000000000172.
    1. Hoagland B, De Boni RB, Moreira RI, Madruga JV, Kallas EG, Goulart SP, et al. Awareness and willingness to use pre-exposure prophylaxis (PrEP) among men who have sex with men and transgender women in Brazil. AIDS Behav. 2017;21(5):1278–1287. doi: 10.1007/s10461-016-1516-5.
    1. Draper BL, Oo ZM, Thein ZW, Aung PP, Veronese V, Ryan C, et al. Willingness to use HIV pre-exposure prophylaxis among gay men, other men who have sex with men and transgender women in Myanmar. J Int AIDS Soc. 2017;20(1):21885. doi: 10.7448/IAS.20.1.21885.
    1. Jalil EM, Grinsztejn B, Velasque L, Makkeda AR, Luz PM, Moreira RI, et al. Awareness, willingness, and PrEP eligibility among transgender women in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr. 2018;79(4):445–452. doi: 10.1097/QAI.0000000000001839.
    1. de Carvalho NP, Mendicino CCP, Cândido RCF, Alecrim DJD, de Pádua CAM. HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review. AIDS Care. 2019;31:1–7.
    1. Poteat T, Wirtz A, Malik M, Cooney E, Cannon C, Hardy WD, et al. A gap between willingness and uptake: Findings from mixed methods research on HIV prevention among black and latina transgender women. J Acquir Immune Defic Syndr. 2019;82(2):131–140. doi: 10.1097/QAI.0000000000002112.
    1. Eaton LA, Matthews DD, Driffin DD, Bukowski L, Wilson PA, Stall RD, et al. A multi-US city assessment of awareness and uptake of pre-exposure prophylaxis (PrEP) for HIV prevention among black men and transgender women who have sex with men. Prev Sci. 2017;18(5):505–516. doi: 10.1007/s11121-017-0756-6.
    1. Restar AJ, Kuhns L, Reisner SL, Ogunbajo A, Garofalo R, Mimiaga MJ. Acceptability of antiretroviral pre-exposure prophylaxis from a cohort of sexually experienced young transgender women in two US cities. AIDS Behav. 2018;22(11):3649–3657. doi: 10.1007/s10461-018-2127-0.
    1. Sevelius JM, Keatley J, Calma N, Arnold E. ‘I am not a man’: trans-specific barriers and facilitators to PrEP acceptability among transgender women. Global Public Health. 2016;11(7–8):1060–1075. doi: 10.1080/17441692.2016.1154085.
    1. Wang Z, Lau JT, Yang X, Cai Y, Gross DL, Ma T, et al. Acceptability of daily use of free oral pre-exposure prophylaxis (PrEP) among transgender women sex workers in Shenyang, China. AIDS Behav. 2017;21(12):3287–3298. doi: 10.1007/s10461-017-1869-4.
    1. Hood JE, Eljallad T, Abad J, Connolly M, Heumann C, Fritz J, et al. Getting pre-exposure prophylaxis to high-risk transgender women: lessons from Detroit, USA. Sexual Health. 2018;15(6):562–569. doi: 10.1071/SH18063.
    1. Rael CT, Martinez M, Giguere R, Bockting W, MacCrate C, Mellman W, et al. Barriers and facilitators to oral PrEP use among transgender women in New York City. AIDS Behav. 2018;22(11):3627–3636. doi: 10.1007/s10461-018-2102-9.
    1. Arrington-Sanders R, Hailey-Fair K, Wirtz AL, Morgan A, Brooks D, Castillo M, et al. Role of structural marginalization, HIV stigma, and mistrust on HIV prevention and treatment among young black latinx men who have sex with men and transgender women: perspectives from youth service providers. AIDS Patient Care STDs. 2020;34(1):7–15. doi: 10.1089/apc.2019.0165.
    1. Bronfenbrenner U. Ecological models of human development. Read Dev Child. 1994;2(1):37–43.
    1. Philbin MM, Parker CM, Parker RG, Wilson PA, Garcia J, Hirsch JS. The promise of pre-exposure prophylaxis for black men who have sex with men: an ecological approach to attitudes, beliefs, and barriers. AIDS Patient Care STDs. 2016;30(6):282–290. doi: 10.1089/apc.2016.0037.
    1. Biello KB, Oldenburg CE, Mitty JA, Closson EF, Mayer KH, Safren SA, et al. The “safe sex” conundrum: anticipated stigma from sexual partners as a barrier to PrEP use among substance using MSM engaging in transactional sex. AIDS Behav. 2017;21(1):300–306. doi: 10.1007/s10461-016-1466-y.
    1. Li J, Berg CJ, Kramer MR, Haardörfer R, Zlotorzynska M, Sanchez TH. An integrated examination of county-and individual-level factors in relation to HIV pre-exposure prophylaxis awareness, willingness to use, and uptake among men who have sex with men in the US. AIDS Behav. 2019;23(7):1721–1736. doi: 10.1007/s10461-018-2334-8.
    1. Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1):163–173. doi: 10.1016/j.jad.2008.06.026.
    1. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–1097. doi: 10.1001/archinte.166.10.1092.
    1. Cameron RP, Gusman D. The primary care PTSD screen (PC-PTSD): development and operating characteristics. Primary Care Psychiatry. 2003;9(1):9–14.
    1. Landovitz RJ, Beymer M, Kofron R, Amico KR, Psaros C, Bushman L, et al. Plasma tenofovir-levels to support adherence to TDF/FTC pre-exposure prophylaxis for HIV prevention in MSM in Los Angeles, California. J Acquir Immune Defic Syndr. 2017;76(5):501. doi: 10.1097/QAI.0000000000001538.
    1. Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018 doi: 10.1128/AAC.01710-17.
    1. Mayring P. Qualitative content analysis. Compan Qual Res. 2004;1:159–176.
    1. Edhlund B, McDougall A. Nvivo 12 essentials: ; 2019.
    1. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357. doi: 10.1093/intqhc/mzm042.
    1. Garnett M, Hirsch-Moverman Y, Franks J, Hayes-Larson E, El-Sadr WM, Mannheimer S. Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in New York city. AIDS Care. 2018;30(1):9–17. doi: 10.1080/09540121.2017.1363364.
    1. Wilson E, Chen Y-H, Pomart WA, Arayasirikul S. Awareness, interest, and HIV pre-exposure prophylaxis candidacy among young transwomen. AIDS Patient Care STDs. 2016;30(4):147–150. doi: 10.1089/apc.2015.0266.
    1. Cahill SR, Keatley J, Wade Taylor S, Sevelius J, Elsesser SA, Geffen SR, et al. “Some of us, we don’t know where we’re going to be tomorrow”. Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco. AIDS Care. 2019;32:1–9.
    1. Brookfield S, Dean J, Forrest C, Jones J, Fitzgerald L. Barriers to accessing sexual health services for transgender and male sex workers: a systematic qualitative meta-summary. AIDS Behav. 2020;24(3):682–696. doi: 10.1007/s10461-019-02453-4.
    1. Reback CJ, Clark KA, Rünger D, Fehrenbacher AE. A promising PrEP navigation intervention for transgender women and men who have sex with men experiencing multiple syndemic health disparities. J Community Health. 2019;44(6):1193–1203. doi: 10.1007/s10900-019-00705-x.
    1. Dankerlui D, Connolly M, Joseph C, Eljallad T, Dodard-Friedman I. P262 PrEP utilization among young transgender women, transgender men, and MSM in an urban community-based setting. BMJ; 2019.
    1. Scott H, Volberding PA. HIV screening and preexposure prophylaxis guidelines: following the evidence. JAMA. 2019;321(22):2172–2174. doi: 10.1001/jama.2019.2590.
    1. Hiransuthikul A, Janamnuaysook R, Himmad K, Kerr SJ, Thammajaruk N, Pankam T, et al. Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. J Int AIDS Soc. 2019;22(7):e25338. doi: 10.1002/jia2.25338.
    1. Eaton LA, Kalichman SC, Price D, Finneran S, Allen A, Maksut J. Stigma and conspiracy beliefs related to pre-exposure prophylaxis (PrEP) and interest in using PrEP among black and white men and transgender women who have sex with men. AIDS Behav. 2017;21(5):1236–1246. doi: 10.1007/s10461-017-1690-0.
    1. McLeroy K, Steckler A, Bibeau D. The social ecology of health promotion interventions. Health Educ Q. 1988;15(4):351–377. doi: 10.1177/109019818801500401.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться